SCHEMBL3477832

SCHEMBL3477832

O=S(=O)(c1ccccc1)N(F)c1ncc(F)s1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.46
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
KMT2A Q03164 4/20 0.36
LOXL2 Q9Y4K0 2/20 0.34
NR1I2 O75469 2/20 0.33
RORC P51449 2/20 0.33
RORA P35398 1/20 0.33
RORB Q92753 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H2 P55055 1/20 0.32
MEN1 O00255 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1093406 0.80 KDM4E (0.47) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094584 0.73 APOBEC3G (0.47) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094210 0.73 APOBEC3G (0.47) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094212 0.72 APOBEC3G (0.46) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094170 0.71 APOBEC3G (0.57) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094685 0.70 APOBEC3G (0.47) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1094961 0.70 APOBEC3G (0.47) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL141091 0.68 APOBEC3G (0.64) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1095059 0.68 APOBEC3G (0.44) APOBEC3GALDH1A1HSD17B10TDP1KMT2A
SCHEMBL1093290 0.67 APOBEC3G (0.52) APOBEC3GALDH1A1HSD17B10TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885HSD17B10 1684/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885HSD17B10 1684/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885HSD17B10 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.